Focused Ultrasound Device Earns FDA Approval to Treat Osteoid Osteomas
The United States Food and Drug Administration (FDA) recently announced that it had approved Profound Medical’s Sonalleve MR-guided High Intensity Focused Ultrasound (MR-HIFU) system for the treatment of osteoid osteoma (OO) in the extremities. This marks the first focused ultrasound regulatory approval that will directly impact pediatric patients, and it is the sixth indication to earn approval in the US.
STAT News annually recognizes a small group of up-and-coming scientists and researchers as “Wunderkinds” – the next generation of scientific superstars. This year, Natasha Sheybani, PhD, was recognized among the awardees.
The COVID-19 pandemic has dramatically impacted all our lives, and the focused ultrasound community is no exception. In early 2020, laboratories around the world were shuttered and clinical trials were paused, resulting in a costly loss in resources and delays of important research that will prolong timelines for promising therapeutic advances. Activities that could be conducted virtually – lab meetings, patient consults, and business development meetings, for example – continued. With restrictions easing in recent months, laboratories are reopening, clinical trials are restarting, and some employees are returning to offices.
Focused Ultrasound Clinical and Research Advances Highlighted at Symposium Media Event
The Foundation hosted a virtual media event on the first day of the Foundation’s 7th International Symposium on Focused Ultrasound to educate top tier media from around the country on the use of focused ultrasound to treat conditions as diverse as Parkinson’s disease, cancer, and psychiatric disorders.